Q1 2023 · 13F-HR/A
Athyrium Capital Management, LPholdings as filed
Filed 2023-05-16 · accession 0001123292-23-000059
$279.1M
Reported value
8
Positions
2023-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03217L106 | — | Amryt Pharma PLC | $129.1M | 46.3% | 8,857,268 | Common | SOLE |
| 74319FAB3 | — | Biora Inc. | $58.1M | 20.8% | 103,500,000 | Common | NONE |
| 682143AG7 | OMER 5.25 02/15/26 | Omeros Corp | $46.5M | 16.7% | 65,136,000 | Common | NONE |
| G6S41R101 | RVLPQ | RVL PHARMACEUTICALS PLC | $16.6M | 5.96% | 14,600,444 | Common | SOLE |
| 682143AE2 | — | Omeros Corp | $11.1M | 3.98% | 11,005,000 | Common | NONE |
| 699374AB0 | — | Paratek Pharmaceuticals Inc. | $7.4M | 2.66% | 9,000,000 | Common | NONE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $5.5M | 1.98% | 1,792,114 | Common | SOLE |
| 74319F305 | — | Biora Inc. | $4.7M | 1.68% | 1,694,481 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.